These results provide direct functional evidence for the influence of inherited genetic variation on ALL risk, highlighting the important and complex roles of CDKN2A–CDKN2B tumour suppressors in leukaemogenesis. The gene discussed is CDKN2B; the disease is acute lymphoblastic leukemia.